Health Condition 1: G968- Other specified disorders of central nervous system
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: NIL: NIL
Sponsors
NIMHANS
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients diagnosed with aneurysmal subarachnoid hemorrhage (aSAH), confirmed by imaging 2)Admission to the ICU/ ward within 72 hours of symptom onset. 3)Consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1) Pre-existing neurological or gastrointestinal disorders 2) Recent use of antibiotics or probiotics within 4 weeks prior to admission. 3) Non-aneurysmal subarachnoid hemorrhage 4) Mycotic aneurysms or aneurysms within arteriovenous malformations. 5) Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification and comparison of gut microbiome composition, short-chain fatty acid (SCFA) levels, and gut integrity biomarkers (zonulin, occludin, claudin-5) between aneurysmal subarachnoid hemorrhage (aSAH) patients and healthy controls, and their association with the development of cerebral vasospasm (CV) and delayed cerebral ischemia (DCI).Timepoint: All biological samples (blood and stool) will be collected within 72 hours of diagnosis in aSAH patients, and once at enrollment in healthy controls. Clinical outcomes (CV and DCI) will be monitored daily for 14 days or until discharge. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Correlation between specific gut microbiome signatures and the occurrence/severity of cerebral vasospasm (CV) and delayed cerebral ischemia (DCI) in aSAH patients. 2)Association of altered short-chain fatty acid (SCFA) levels (acetate, propionate, and butyrate) with clinical outcomes in aSAH, including CV and DCI. 3)Correlation between blood levels of gut barrier integrity biomarkers (zonulin, occludin, claudin-5) and radiological or clinical evidence of cerebral vasospasm and delayed cerebral ischemia. 4)Comparison of gut microbiome diversity (alpha and beta diversity) between aSAH patients and healthy controls. 5)Exploratory identification of potential microbial or biomarker-based predictive tools for clinical outcomes in aSAH.Timepoint: All biological samples (blood and stool) will be collected within 72 hours of diagnosis in aSAH patients, and once at enrollment in healthy controls. Clinical outcomes (CV and DCI) will be monitored daily for 14 days or until discharge. | — |
Countries
India
Contacts
Public ContactDr Dhaval Shukla
NIMHANS
Outcome results
None listed